Cargando…
Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults
BACKGROUND: Centanafadine is an inhibitor of reuptake transporters for norepinephrine (NET), dopamine (DAT) and serotonin (SERT). AIMS: This phase 1, adaptive-design positron emission tomography study investigated the occupancy time course of NET, DAT, and SERT and the relationship to centanafadine...
Autores principales: | Matuskey, David, Gallezot, Jean-Dominique, Nabulsi, Nabeel, Henry, Shannan, Torres, Kristen, Dias, Mark, Angarita, Gustavo A, Huang, Yiyun, Shoaf, Susan E, Carson, Richard E, Mehrotra, Shailly |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912308/ https://www.ncbi.nlm.nih.gov/pubmed/36515395 http://dx.doi.org/10.1177/02698811221140008 |
Ejemplares similares
-
2181 Age-related change in 5-HT6 receptor availability in healthy male volunteers measured with 11C-GSK215083 PET
por: Radhakrishnan, Rajiv, et al.
Publicado: (2018) -
Drug characteristics derived from kinetic modeling: combined (11)C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A
por: Naganawa, Mika, et al.
Publicado: (2022) -
Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies
por: Wigal, Sharon B, et al.
Publicado: (2020) -
RF12 | PSUN106 Quantifying Liver and Brain Levels of 11β-hydroxysteroid Dehydrogenase Type 1 in Obesity Using Positron Emission Tomography Imaging
por: Bini, Jason, et al.
Publicado: (2022) -
Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging
por: Matuskey, David, et al.
Publicado: (2020)